DXP-106 / Singlomics - LARVOL DELTA

DXP-106, an anti-IL1RAP monoclonal antibody with enhanced ADCC activity, exhibits both in vitro and in vivo anti-tumor effects and has successfully completed IND-enabling studies (AACR 2026) - "DXP-106 is a potent monoclonal antibody that specifically binds to a unique epitope on IL1RAP, broadly inhibits all six IL-1 family signaling pathways, and shows robust anti-tumor activity both in vitro and in vivo. IND-enabling studies have been successfully completed, and the first-in-human (FIH) clinical trial is planned for the first quarter of 2026."

ADC • First-in-human • Preclinical • Oncology • Squamous Cell Carcinoma • IL1B • IL1R1 • IL1RAP • IL33